The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer
Theranostics · 2024
DOI: 10.7150/thno.93236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Minsu Park und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 02841, Republic of Korea. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Drug Resistance, Neoplasm, Breast Neoplasms, Trastuzumab. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University, Seoul 02841, Republic of Korea.
- Brain Korea 21 Program for Biomedical Science, Korea University College of Medicine, Korea University, Seoul 02841, Republic of Korea.
- Department of Biomedical Research Center, Korea University Guro Hospital, Korea University, Seoul 08308, Republic of Korea.
- Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, South Australia 5000, Australia.
- Faculty of Pharmacy, PHENIKAA University, Hanoi 12116, Vietnam.
- Department of Organic Chemistry, Hanoi University of Pharmacy, Hanoi 10000, Vietnam.
Zitieren
APA
Park, M., Jung, E., Park, J. M., Park, S., Ko, D., Seo, J., Kim, S., Nam, K. D., Kang, Y. K., Farrand, L., Hoang, V. H., Nguyen, C. T., La, M. T., Nam, G., Park, H. J., Ann, J., Lee, J., Kim, Y. J., Kim, J. Y., & Seo, J. H. (2024). The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics. https://doi.org/10.7150/thno.93236
Vancouver
Park M, Jung E, Park JM, Park S, Ko D, Seo J, et al. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics. 2024. doi:10.7150/thno.93236
BibTeX
@article{Park2024,
author = {Park, Minsu and Jung, Eunsun and Park, Jung Min and Park, Soeun and Ko, Dongmi and Seo, Juyeon and Kim, Seongjae and Nam, Kee Dal and Kang, Yong Koo and Farrand, Lee and Hoang, Van-Hai and Nguyen, Cong-Truong and La, Minh Thanh and Nam, Gibeom and Park, Hyun-Ju and Ann, Jihyae and Lee, Jeewoo and Kim, Yoon-Jae and Kim, Ji Young and Seo, Jae Hong},
title = {The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer},
journal = {Theranostics},
year = {2024},
doi = {10.7150/thno.93236}
}
EUVIMED